within Pharmacolibrary.Drugs.ATC.R;

model R01AX10
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.8333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 84 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.338,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01AX10</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ipratropium bromide is an anticholinergic medication primarily used as a bronchodilator for the treatment and management of chronic obstructive pulmonary disease (COPD) and asthma. It works by inhibiting the muscarinic acetylcholine receptors in bronchial smooth muscle, leading to bronchodilation. Ipratropium bromide is approved for use in many countries and is commonly administered via inhalation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult healthy individuals after intranasal administration.</p><h4>References</h4><ol><li><p>Wood, CC, et al., &amp; MacGregor, T (1995). Product characteristics and pharmacokinetics of intranasal ipratropium bromide. <i>The Journal of allergy and clinical immunology</i> 95(5 Pt 2) 1111–1116. DOI:<a href=&quot;https://doi.org/10.1016/s0091-6749(95)70214-8&quot;>10.1016/s0091-6749(95)70214-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7751527/&quot;>https://pubmed.ncbi.nlm.nih.gov/7751527</a></p></li><li><p>Naclerio, RM (1998). Optimizing treatment options. <i>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</i> 28 Suppl 6 54–59. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2222.1998.0280s6054.x&quot;>10.1046/j.1365-2222.1998.0280s6054.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9988437/&quot;>https://pubmed.ncbi.nlm.nih.gov/9988437</a></p></li><li><p>Laurikainen, E, et al., &amp; Isalo, E (1988). Evaluation of the systemic anticholinergic activity of nasally administered ipratropium bromide. <i>Rhinology</i> 26(2) 133–138. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2972054/&quot;>https://pubmed.ncbi.nlm.nih.gov/2972054</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01AX10;
